296 related articles for article (PubMed ID: 18460894)
1. Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses.
Michael D; Grando SA
Curr Dir Autoimmun; 2008; 10():333-43. PubMed ID: 18460894
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Khalili B; Bahna SL
Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
[TBL] [Abstract][Full Text] [Related]
3. IVIG for the treatment of toxic epidermal necrolysis.
Mittmann N; Chan BC; Knowles S; Shear NH
Skin Therapy Lett; 2007 Feb; 12(1):7-9. PubMed ID: 17361314
[TBL] [Abstract][Full Text] [Related]
4. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options.
Teo L; Tay YK; Liu TT; Kwok C
Singapore Med J; 2009 Jan; 50(1):29-33. PubMed ID: 19224081
[TBL] [Abstract][Full Text] [Related]
5. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
French LE; Trent JT; Kerdel FA
Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
[TBL] [Abstract][Full Text] [Related]
6. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
Chen J; Wang B; Zeng Y; Xu H
Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.
Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS
Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523
[TBL] [Abstract][Full Text] [Related]
8. [Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases].
Molgó M; Carreño N; Hoyos-Bachiloglu R; Andresen M; González S
Rev Med Chil; 2009 Mar; 137(3):383-9. PubMed ID: 19621180
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
Ririe MR; Blaylock RC; Morris SE; Jung JY
J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
11. Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Teraki Y; Kawabe M; Izaki S
J Allergy Clin Immunol; 2013 Mar; 131(3):907-9. PubMed ID: 23083672
[No Abstract] [Full Text] [Related]
12. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
[TBL] [Abstract][Full Text] [Related]
13. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Borchers AT; Lee JL; Naguwa SM; Cheema GS; Gershwin ME
Autoimmun Rev; 2008 Sep; 7(8):598-605. PubMed ID: 18603022
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases].
Mouthon L; Hurez V; Kazatchkine M
Ann Med Interne (Paris); 1993; 144(8):506-13. PubMed ID: 8179238
[TBL] [Abstract][Full Text] [Related]
15. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis.
Paquet P; Kaveri S; Jacob E; Pirson J; Quatresooz P; Piérard GE
Exp Dermatol; 2006 May; 15(5):381-6. PubMed ID: 16630079
[TBL] [Abstract][Full Text] [Related]
16. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding.
French LE
Allergol Int; 2006 Mar; 55(1):9-16. PubMed ID: 17075281
[TBL] [Abstract][Full Text] [Related]
17. Toxic epidermal necrolysis and intravenous immunoglobulin: a review.
Trent J; Halem M; French LE; Kerdel F
Semin Cutan Med Surg; 2006 Jun; 25(2):91-3. PubMed ID: 16908399
[TBL] [Abstract][Full Text] [Related]
18. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI
Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
[TBL] [Abstract][Full Text] [Related]
19. Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature.
Metry DW; Jung P; Levy ML
Pediatrics; 2003 Dec; 112(6 Pt 1):1430-6. PubMed ID: 14654625
[TBL] [Abstract][Full Text] [Related]
20. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin.
Rütter A; Luger TA
J Am Acad Dermatol; 2001 Jun; 44(6):1010-24. PubMed ID: 11369915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
